Navigation Links
EMD Serono to Adopt Revised and Strengthened PhRMA Code
Date:7/10/2008

- Revised Code Demonstrates Strong Commitment to Ethical Information

Exchange between Physician Community and Leading Biotechnology and

Pharmaceutical Companies -

ROCKLAND, Mass., July 10 /PRNewswire/ -- EMD Serono, Inc. announced today that the company has adopted and will fully implement, the revised and strengthened PhRMA Code on Interactions with Healthcare Professionals. The revised voluntary Code, which builds on the prior 2002 version, was approved unanimously by the PhRMA Board of Directors and announced by PhRMA earlier today. The revised Code reaffirms that interactions between company representatives and healthcare professionals should be focused on informing healthcare professionals about the benefits and risks of medicines to help enhance patient care, providing scientific and educational information, and supporting medical research and takes effect in January 2009. The revised Code reinforces the commitment of America's leading pharmaceutical research and biotechnology companies, including EMD Serono, to provide up-to-date, accurate information to healthcare providers about life-saving and life-enhancing medicines.

The adoption of the revised Code reaffirms EMD Serono's pledge to focus interactions between company representatives and healthcare professionals on informing them of our products and advancing tomorrow's medicines. EMD Serono adopted the prior version of the Code in 2002 and actively worked with PhRMA on enhancements to the Code. EMD Serono fully supports the underlying purpose of the enhanced Code to ensure that interactions between industry and healthcare professionals meet the highest ethical standards and benefit patients. EMD Serono has implemented a comprehensive company-wide Compliance Program; introduction of the revised PhRMA code aligns with the company's commitment to best practices and ethics in serving the medical community and patients.

"EMD Serono was an early cont
'/>"/>

SOURCE EMD Serono, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
2. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
3. EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts
4. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
5. BioLife Solutions CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells
6. Coley Pharmaceutical Group Adopts Shareholder Rights Plan
7. Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
8. Monsanto Company Executives Adopt 10b5-1 Trading Plans
9. YM Biosciences announces adoption of renewed Shareholders Rights Plan
10. Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against Superbugs
11. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Edison Investment Research, ... the initiation of full coverage of BioAlliance ... and marketing products for orphan oncology and ... (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison has today ... merits of BioAlliance Pharma, focusing in particular ...
(Date:6/18/2013)... Toronto, Canada (PRWEB) June 18, 2013 ... FDA oversight of pharmaceutical advertising and promotion, and ... , Viewers will learn how to apply these ... enforcement examples:, ,     The fundamentals on ... advertising and promotional labeling ,     Assessing traditional ...
(Date:6/18/2013)... , June 18, 2013 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/cmbgcv/north_american ) has announced the ... Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market ... Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] ... 2017" report to their offering. ...
(Date:6/18/2013)... June 18, 2013 Earlier this year, Google ... platform. As this directly impacts the core component of ... one of the most sweeping updates since its inception in ... Technologies recently posted a very informative article on ... ‘must-have’ upgrade date for enhanced campaigns . Only ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 2Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 3
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... today announced that it has received clearance ... to begin marketing additional,diameters of its Quill(TM) ... The Quill(TM) SRS PDO is a longer-lasting ...
... fraught with,flare-ups of pain, or breakthrough pain, may ... new easy-to-use oral drug delivery system developed by,BioDelivery ... Cancer patients frequently experience two types of pain: ... continuous pain,present for long periods of time, and ...
... the Fourth ... Quarter, FRAZER, ... a 12-week, Phase 3 clinical,trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in ... The study achieved statistical significance on the primary,endpoint. Results across the 12 ...
Cached Biology Technology:Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 2Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 3Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 4Novel Technology Breaks Through Cancer Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5
(Date:6/18/2013)... Research Council, Laboratory of Molecular Biology, has been ... Young Investigator Award. Torrent is being recognized for ... algorithm to predict antimicrobial regions in proteins. Luis ... now applying this algorithm to interrogate full genomes ... with very appealing results." , Torrent obtained ...
(Date:6/18/2013)... The herbal extract of a yellow-flowered mountain plant long ... lifespan of fruit fly populations by an average of ... it,s how Rhodiola rosea , also ... attention of study leaders Mahtab Jafari and Sam Schriner. ... manner completely unrelated to dietary restriction and affects different ...
(Date:6/18/2013)... shows that weight gain and increased head size in the first ... at early school age. , The study was led by University ... 13,800 children who were born full-term. , The results, published in ... put on 40% of their birthweight in the first four weeks ... six years of age, compared with babies who only put on ...
Breaking Biology News(10 mins):The American Society for Microbiology honors Marc Torrent 2Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2IQ link to baby's weight gain in first month 2
... announce 7.5 million of funding for a series of projects ... H1N1 2009 or ,swine flu,. The research will look ... pig and human populations, and in hospital intensive care units. ... reported in Mexico in March this year. In June, as ...
... researchers from Carnegie Mellon University, Goettingen Medical School in ... Kingdom have received a Human Frontiers Science Program (HFSP) ... better understand the "cellular GPS" system that guides neurons ... In the course of the development and repair of ...
... CORVALLIS, Ore. - Penguins that died 44,000 years ago ... challenge the accuracy of traditional genetic aging measurements, and ... of many specimens by 200 to 600 percent. ... DNA testing to be 100,000 years old may actually ...
Cached Biology News:£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 2£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 3£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 4Carnegie Mellon researchers to develop probes to study cellular GPS 2Ancient penguin DNA raises doubts about accuracy of genetic dating techniques 2
... with a modular approach to instrument control, ... Plus NDS family provides modular software components ... management, giving you the flexibility to choose ... now and that can grow as your ...
... Workgroup solution is a highly scalable ... expression data in a workgroup or ... in over 40 leading pharmaceutical, biotechnology, ... GeneSpring Workgroup streamlines genomics research at ...
... designed for proteomic scale kinase profiling, ... and drug discovery research built on ... on-chip synthesis platform. These microarrays are ... Protein Kinase Substrate - Peptide Microarray ...
... 18 amino acid synthetic peptide whose sequences are derived from mouse ... carboxy terminus): S(21) - S - M - P - L ... A - I - D - K - K - I ... peptide may be used for neutralization and control experiments with the ...
Biology Products: